PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay.
GlaxoSmithKline and Valeant marketed their epilepsy drug ezogabine for just six years before pulling it for “commercial reasons.” Now, Xenon Pharmaceuticals is taking a stab at repurposing the drug for a rare, difficult-to-treat form of pediatric epilepsy caused by a genetic mutation.
GSK has temporarily halted production of Ventolin HFA inhalers at its plant in Zebulon, North Carolina while it investigates customer complaints.
SciFluor Receives US Patent for KCNQ2/3 Activator to Treat Epilepsy and Neurological Disorders